Dear editor
I read with great interest the recent manuscript entitled "Demodex blepharitis: clinical perspectives" by Fromstein et al in Clinical Optometry.
1 I wish to commend the authors on a thorough and well-written review of the subject. However, I feel compelled to point out one very controversial point that I believe is erroneous and unfounded. In their discussion of management, the authors write, "In addition to branded Avenova ® (NovaBay Pharmaceuticals, Emeryville, CA, USA), some mild generic lid cleansers contain detergents or hypochlorous acid, which are active against bacterial, fungal, and viral pathogens. Hypochlorous acid has been shown to be effective in controlling biofilms and in wound healing. Studies have shown a reduction in the number of Demodex mites with management of hypochlorous acid."
1 It is the final sentence in this passage to which I take exception. In support of this claim, the authors cite two publications: "The efficacy of tea tree face wash, 1,2-octanediol and microblepharoexfoliation in treating Demodex folliculorum blepharitis" 2 and "Short-term comfort responses associated with the use of eyelid cleansing products to manage Demodex folliculorum". 3 Having reviewed these original studies, I can find no mention whatsoever of hypochlorous acid in the former paper by Murphy et al. 2 Regarding the latter publication, while hypochlorous acid was one of the solutions evaluated by Ngo et al, 3 this particular study assessed subjective comfort primarily, with secondary measures including visual acuity, noninvasive tear breakup time, anterior segment biomicroscopy, central corneal sensitivity and corneal staining. Assessment of Demodex mites in terms of prevalence or survival was not a reported outcome. In fact, the subjects in this study were described as "non-contact lens wearers, asymptomatic (ocular surface disease index [OSDI] score ≤22) and were free from health conditions or ocular disease that could potentially affect an outcome variable". In other words, these were healthy, young (mean age 26±6 years) subjects without demodicosis.
The myth that hypochlorous acid has any significant demodicidal activity has been intimated and perpetuated for several years, primarily in marketing materials and "advertorials" related to Avenova ® . However, there is no clinical evidence to support this assertion. To the contrary, my laboratory has demonstrated that 0.1% hypochlorous acid solution has virtually no effect on live, adult Demodex mites in vitro. In compari- Clinical Optometry is an international, peer-reviewed, open access journal publishing original research, basic science, clinical and epidemiological studies, reviews and evaluations on clinical optometry. All aspects of patient care are addressed within the journal as well as the practice of optometry including economic and business analyses. Basic and clinical research papers are published that cover all aspects of optics, refraction and its application to the theory and practice of optometry. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress. com/testimonials.php to read real quotes from published authors. It is unfortunate that Dr Kabat's study was not available prior to our paper submission. We, the authors of "Demodex blepharitis: clinical perspectives", 1 thank Dr Kabat for his comments and for sharing his work with us. We look forward to learning more about the details of Dr Kabat's study and hope that the presentation of his work becomes a published manuscript.
Dovepress

117
Disclosure
Jennifer S Harthan serves as a consultant and advisory board member for Allergan and Shire Pharmaceuticals, key opinion leader for SynergEyes, and consultant and lecturer for Metro Optics. Dominick L Opitz serves as a consultant for Shire Pharmaceuticals and as a speaker and consultant for Bausch + Lomb. Stephanie R Fromstein and Jaymeni Patel report no conflicts of interest in this communication.
